Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 17, Issue 12, 1998, Pages 828-833

  O'Doherty, B ^a   Muller, O ^a  

^a NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; COMMUNICABLE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERANCE; ERADICATION THERAPY; EVALUATION AND FOLLOW UP; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; STATISTICAL ANALYSIS; TASTE AVERSION;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CLARITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

EID: 0032406880     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050201     Document Type: Article

References (25)

1. 1. Mazzei T, Mini E, Novelli A, Periti P: Chemistry and mode of action of macrolides. Journal of Antimicrobial Chemotherapy (1993) 31:1-9
2. 2. Retsema JA, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, Borovoy R, Brennan L, Mason R: Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrobial Agents and Chemotherapy (1987) 31:1939-1947
3. 3. Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes PB: Comparative in vitro activities of new 14-, 15-and 16-membered macrolides. Antimicrobial Agents and Chemotherapy (1988) 32:1710-1719
4. 4. Neu HC: The development of macrolides: clarithromycin in perspective. Journal of Antimicrobial Chemotherapy (1991) 27, Supplement A:1-9
5. 5. Aronoff SC, Laurent C, Jacobs MR: In-vitro activity of erythromycin, roxithromycin and CP-62,993 against common paediatric pathogens. Journal of Antimicrobial Chemotherapy (1987) 19:275-276
6. 6. Goldstein FW, Emirian MF, Coutrot A, Acar JF: Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae. Journal of Antimicrobial Chemotherapy (1990) 25, Supplement A:25-28
7. 7. Barry AL, Pfaller MA, Fuchs PC, Packer RR: In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from US medical centers in 1992 and 1993. Antimicrobial Agents and Chemotherapy (1994) 38:2419-2425
8. 8. Felmingham D, Robbins MJ, Sanghrajka M, Leakey A, Ridgway GL: The in vitro activity of some 14-, 15-, and 16-membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum. Drugs under Experimental and Clinical Research (1991) 17:91-99
9. 9. Edelstein PH, Edelstein MAC: In vitro activity of azithromycin against clinical isolates of Legionella species. Antimicrobial Agents and Chemotherapy (1991) 35:180-181
10. 10. Chin NX, Saha G, Labthavikul P, Neu HC: Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. Antimicrobial Agents and Chemotherapy (1987) 31:463-466
11. 11. Peters DH, Clissold SP: Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs (1992) 44:117-164
12. 12. Brown S, Barry AL, Burton P: Susceptibility surveillance of US respiratory pathogen isolates to newer macrolide and azalide antibiotics. International Journal of Antimicrobial Agents (1996) 7:53-58
13. 13. Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeybourne D: Azithromycin concentrations at the sites of pulmonary infection. European Respiratory Journal (1990) 3:886-890
14. 14. Myburgh J, Nagel GJ, Petschel E: The efficacy and tolerance of a three-day course of azithromycin in the treatment of community-acquired pneumonia. Journal of Antimicrobial Chemotherapy (1993) 31:1630-1639
15. 15. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disc susceptibility test: Approved standard M2-A5. NCCLS, Villanova, PA (1994)
16. 16. Doern GV, Brueggemann A, Holley HP Jr, Rauch AM: Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrobial Agents and Chemotherapy (1996) 40:1208-1213
17. 17. Pontani D, Washton H, Bouchillon S, Johnson J: Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. European Journal of Clinical Microbiology & Infectious Diseases (1998) 17:413-419
18. 18. Hopkins SJ: Clinical toleration and safety of azithromycin in adults and children. Reviews of Contemporary Pharmacotherapeutics (1994) 5:383-389
19. 19. Hopkins S, Williams D: Five-day azithromycin in the treatment of patients with community-acquired pneumonia. Current Therapeutic Research (1995) 56:915-925
20. 20. Bradbury F: Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infections. Journal of Antimicrobial Chemotherapy (1995) 31:153-162
21. 21. Pozzi E, Grossi E, Pecori A, and the Azithromycin Research Group: Azithromycin versus clarithromycin in the treatment of acute exacerbations of chronic bronchitis. Current Therapeutic Research (1994) 55:759-764
22. 22. Branthwaite A, Pechère J-C: Pan-European survey of patients' attitudes to antibiotics and antibiotic use. Journal of International Medical Research (1996) 24:229-238
23. 23. Cockburn J, Gibberd RW, Reid AL: Determinants of non-compliance with short-term antibiotic regimens. British Medical Journal (1987) 295:814-818
24. 24. Colcher IS, Bass JW: Penicillin treatment of streptococcal pharyngitis: a comparison of schedules and the role of specific counselling. Journal of the American Medical Association (1972) 222:657-659
25. 25. Daschner F, Magret W: Treatment of recurrent urinary tract infections in children. II. Compliance of parents and children with antibiotic therapy regimen. Acta Paediatrica Scandinavica (1975) 64:105-108